AstraZeneca and Daiichi Sankyo presented Phase 3 data showing Enhertu (trastuzumab deruxtecan) can improve outcomes when used earlier in breast cancer, potentially moving the ADC into curative‑intent settings. Company presentations at ESMO detailed response rates and event‑free survival signals that supported expansion beyond metastatic disease. Discussants including Dana‑Farber’s Harold Burstein framed the results as part of ADCs ‘‘moving up the ladder’’ from late‑line salvage therapy toward earlier stages. The findings will drive regulatory filings and trials testing Enhertu as neoadjuvant or adjuvant therapy.